Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine the safety and effectiveness of the SafeFlo filter for permanent protection against pulmonary emboli. All patients will be selected to receive the filter according to the stated inclusion / exclusion criteria after consultation between the attending physician and interventional radiologist. Patients with a permanent implantation will be followed for up to 6 months. Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization. The proportion of permanent filter patients considered to be a clinical success will be the primary efficacy parameter.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single arm | Experimental | SafeFlo IVC Filter |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SafeFlo IVC Filter | Device | SafeFlo IVC Filter |
|
| Measure | Description | Time Frame |
|---|---|---|
| Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization. | 6 months follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of patients with successful deployment of the filter will be calculated and presented with a 95% exact confidence interval. | 3 and 6 months follow-up |
Not provided
Inclusion Criteria:
Traditional indications for vena cava filter in patients with established DVT or PE, including (40):
Patients with proven Pulmonary Embolus (PE) or Deep Vein Thrombosis (DVT) and one or more of the following:
Contraindication to anticoagulation
Complication of anticoagulation
Failure of anticoagulation
Poor compliance with anticoagulation medications
Extended indications for vena cava filter placement in patients with established DVT or PE, including the following (31, 40):
High risk trauma or orthopedic patients who cannot receive anticoagulation because of increased bleeding risk, and have one or more of the following injury patterns (31, 40):
Patients undergoing long-term immobilization (e.g., ICU or Surgical oncology)
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jacob Cynamon, Dr. | Montefiore Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Holy Name Hospital | Teaneck | New Jersey | United States | |||
| Mt. Sinai Hospital |
Not provided
| Label | URL |
|---|---|
| Sponsor Website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Manhattan |
| New York |
| United States |
| Montefiore Medical Center | The Bronx | New York | United States |
| University Hospital Vienna | Vienna | Austria |
| 251 Air Force Hospital | Athens | Greece |
| Rabin Medical Center | Petah Tikva | Israel |
| Universitas Hospital | Bloemfontein | South Africa |
| Queen Margaret Hospital | Dumfermline | Scotland | United Kingdom |
| ID | Term |
|---|---|
| D011655 | Pulmonary Embolism |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D004617 | Embolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided